Left dorsolateral prefrontal transcranial magnetic stimulation (TMS)

Sleep factor changes during treatment in patients with pharmacoresistant major depressive disorder

Peter B. Rosenquist, Andrew Krystal, Karen L. Heart, Mark A. Demitrack, William Vaughn McCall

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

As they alleviate major depressive disorder, antidepressant therapies may improve associated sleep disturbances, but may also have inherent sedating or activating properties. We examined sleep changes during a multicenter, sham-controlled, trial of transcranial magnetic stimulation (TMS) therapy for pharmacoresistant MDD. Medication-free outpatients (N=301) were randomized to receive active (N=155) or sham (N=146) TMS for 6 weeks. Depression severity was rated with the Montgomery-Asberg Depression Rating Scale, the 24-item Hamilton Depression Scale (HAMD), and the Inventory of Depressive Symptoms-Self Report (IDS-SR). Assessments were performed at baseline, 2, 4, and 6 week time points. Sleep was assessed using the HAMD and IDS-SR sleep factors; comparison between treatment groups employed ANCOVA model. No significant differences were identified between the active and sham treatment groups in either the HAMD or IDS-SR sleep factor scores at any time during treatment. Sleep difficulty as an adverse event over the length of the study did not differ between active and sham treatment. Stratified by end of acute treatment responder status, there was a statistically significant improvement in both the HAMD sleep factor score and the IDS-SR sleep factor during acute treatment in both the active and sham treatment conditions. TMS exerts no intrinsic effect upon sleep in patients with MDD.

Original languageEnglish (US)
Pages (from-to)67-73
Number of pages7
JournalPsychiatry Research
Volume205
Issue number1-2
DOIs
StatePublished - Jan 30 2013

Fingerprint

Transcranial Magnetic Stimulation
Major Depressive Disorder
Sleep
Depression
Self Report
Therapeutics
Equipment and Supplies
Placebos
Magnetic Field Therapy
Antidepressive Agents
Outpatients

Keywords

  • Adverse events
  • Clinical trial
  • Insomnia
  • Major depression
  • Sleep
  • Transcranial magnetic stimulation

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Left dorsolateral prefrontal transcranial magnetic stimulation (TMS) : Sleep factor changes during treatment in patients with pharmacoresistant major depressive disorder. / Rosenquist, Peter B.; Krystal, Andrew; Heart, Karen L.; Demitrack, Mark A.; McCall, William Vaughn.

In: Psychiatry Research, Vol. 205, No. 1-2, 30.01.2013, p. 67-73.

Research output: Contribution to journalArticle

@article{2cb0b26dc0154684b86924fe676e15d4,
title = "Left dorsolateral prefrontal transcranial magnetic stimulation (TMS): Sleep factor changes during treatment in patients with pharmacoresistant major depressive disorder",
abstract = "As they alleviate major depressive disorder, antidepressant therapies may improve associated sleep disturbances, but may also have inherent sedating or activating properties. We examined sleep changes during a multicenter, sham-controlled, trial of transcranial magnetic stimulation (TMS) therapy for pharmacoresistant MDD. Medication-free outpatients (N=301) were randomized to receive active (N=155) or sham (N=146) TMS for 6 weeks. Depression severity was rated with the Montgomery-Asberg Depression Rating Scale, the 24-item Hamilton Depression Scale (HAMD), and the Inventory of Depressive Symptoms-Self Report (IDS-SR). Assessments were performed at baseline, 2, 4, and 6 week time points. Sleep was assessed using the HAMD and IDS-SR sleep factors; comparison between treatment groups employed ANCOVA model. No significant differences were identified between the active and sham treatment groups in either the HAMD or IDS-SR sleep factor scores at any time during treatment. Sleep difficulty as an adverse event over the length of the study did not differ between active and sham treatment. Stratified by end of acute treatment responder status, there was a statistically significant improvement in both the HAMD sleep factor score and the IDS-SR sleep factor during acute treatment in both the active and sham treatment conditions. TMS exerts no intrinsic effect upon sleep in patients with MDD.",
keywords = "Adverse events, Clinical trial, Insomnia, Major depression, Sleep, Transcranial magnetic stimulation",
author = "Rosenquist, {Peter B.} and Andrew Krystal and Heart, {Karen L.} and Demitrack, {Mark A.} and McCall, {William Vaughn}",
year = "2013",
month = "1",
day = "30",
doi = "10.1016/j.psychres.2012.09.011",
language = "English (US)",
volume = "205",
pages = "67--73",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Left dorsolateral prefrontal transcranial magnetic stimulation (TMS)

T2 - Sleep factor changes during treatment in patients with pharmacoresistant major depressive disorder

AU - Rosenquist, Peter B.

AU - Krystal, Andrew

AU - Heart, Karen L.

AU - Demitrack, Mark A.

AU - McCall, William Vaughn

PY - 2013/1/30

Y1 - 2013/1/30

N2 - As they alleviate major depressive disorder, antidepressant therapies may improve associated sleep disturbances, but may also have inherent sedating or activating properties. We examined sleep changes during a multicenter, sham-controlled, trial of transcranial magnetic stimulation (TMS) therapy for pharmacoresistant MDD. Medication-free outpatients (N=301) were randomized to receive active (N=155) or sham (N=146) TMS for 6 weeks. Depression severity was rated with the Montgomery-Asberg Depression Rating Scale, the 24-item Hamilton Depression Scale (HAMD), and the Inventory of Depressive Symptoms-Self Report (IDS-SR). Assessments were performed at baseline, 2, 4, and 6 week time points. Sleep was assessed using the HAMD and IDS-SR sleep factors; comparison between treatment groups employed ANCOVA model. No significant differences were identified between the active and sham treatment groups in either the HAMD or IDS-SR sleep factor scores at any time during treatment. Sleep difficulty as an adverse event over the length of the study did not differ between active and sham treatment. Stratified by end of acute treatment responder status, there was a statistically significant improvement in both the HAMD sleep factor score and the IDS-SR sleep factor during acute treatment in both the active and sham treatment conditions. TMS exerts no intrinsic effect upon sleep in patients with MDD.

AB - As they alleviate major depressive disorder, antidepressant therapies may improve associated sleep disturbances, but may also have inherent sedating or activating properties. We examined sleep changes during a multicenter, sham-controlled, trial of transcranial magnetic stimulation (TMS) therapy for pharmacoresistant MDD. Medication-free outpatients (N=301) were randomized to receive active (N=155) or sham (N=146) TMS for 6 weeks. Depression severity was rated with the Montgomery-Asberg Depression Rating Scale, the 24-item Hamilton Depression Scale (HAMD), and the Inventory of Depressive Symptoms-Self Report (IDS-SR). Assessments were performed at baseline, 2, 4, and 6 week time points. Sleep was assessed using the HAMD and IDS-SR sleep factors; comparison between treatment groups employed ANCOVA model. No significant differences were identified between the active and sham treatment groups in either the HAMD or IDS-SR sleep factor scores at any time during treatment. Sleep difficulty as an adverse event over the length of the study did not differ between active and sham treatment. Stratified by end of acute treatment responder status, there was a statistically significant improvement in both the HAMD sleep factor score and the IDS-SR sleep factor during acute treatment in both the active and sham treatment conditions. TMS exerts no intrinsic effect upon sleep in patients with MDD.

KW - Adverse events

KW - Clinical trial

KW - Insomnia

KW - Major depression

KW - Sleep

KW - Transcranial magnetic stimulation

UR - http://www.scopus.com/inward/record.url?scp=84872618893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872618893&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2012.09.011

DO - 10.1016/j.psychres.2012.09.011

M3 - Article

VL - 205

SP - 67

EP - 73

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 1-2

ER -